Get started
ACADIA Pharmaceuticals Inc.ACADIA Pharmaceuticals Inc.ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

ACAD trade ideas

Cup and HandleACAD is not quite to yearly cup and handle break out, or basically the yearly high. Acad looks to have been in a big fat rising wedge pattern then media and powers above, decided to end our society as we know it at least for 2020, and down she went. Earnings were 11-4 and they missed on revenue so I am not even sure what propels this one..just seems it is usually a contender. NV and OBV are both high and short interest is a bit higher than I like at 6.7% Some folks enter on the handle if they feel that price is secure, which we never really know for sure. Is not how I learned but have done it with success. I have entered at mid cup before I knew it was a cup and handle..lol. Support at that gap and at 53ish.. One thing I look back on when this name pops up, is I need to go with my gut, and not what someone tells you or what talking heads say etc..lol. I saw this at the bottom and my gut told me to buy it. In fact, I think I made a post on bottom fishing and someone commented that I should wait or something. I do not recall. There was no pattern, just a bottom..then I just forgot about it. Lesson learned..and we keep on learning them. I looked at this using heiken-ashi candles and appears bullish. These are different from regular candles and filter out some of the noise and can help identify trends. Heiken-ashi candles are opposite in some ways than traditional candles. Hollow green candles with no lower shadows are used to signal strong buying pressure (vs the hammer in traditional candles where the wick is on the bottom and there is no upper wick), while filled black (or red) candles with no upper shadow are used to identify a strong downtrend. Heikin-Ashi dojis are similar to traditional candlestick dojis, they have small bodies and long upper and lower shadows. There are no gaps on a Heikin-Ashi chart (which I do not like) as the current candle is calculated using information from the previous candle. One candle alone has no meaning. Interesting to look at these sometimes when trying to figure out what the heck is going on (o: Anyway, this is not a recommendation and patterns fail. This is just a pattern that it forming. Look for a good entry and go with your gut! Happy Holidays!
NASDAQ:ACADLong
by lauralea
Rising Wedge Falling Wedge If I were to go long on this one, I would take the R that will possibly be encountered at bottom of gap down at 48.15ish in to account and possibly use that as a target as well unless it breaks through it unexpectedly. If it stalls there, I would perhaps sell and wait for a pull back to re-enter ACAD has not fallen the entire drop to Point A of the rising wedge, and it may not. Remains to be seen A lot of R overhead. Appears buying kicked in at $36.32 The falling wedge could be bullish and price has broken upper trend line but a confirmed uptrend is not in place from what I see Trade safely. Not a recommendation
NASDAQ:ACAD
by lauralea
6
ACAD ACADIA PHARMACEUTICALS INC 5X GAINS COMING SOON (HODL)buy ACAD entry 1 $44.50 & entry 2 $42.50 sl $38.50 tp.1 $50.50 tp.2 $55.50 Tp.3 $60.00 Tp.4 $70.50 Tp.5 $80.00 many products releasing soon Sector: Health Technology Industry: Biotechnology Employees: 503 ACADIA Pharmaceuticals , Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA. Valuation Market Capitalization 8.373B Enterprise Value ( MRQ ) 5.922B Enterprise Value/EBITDA ( TTM ) — Total Shares Outstanding ( MRQ ) 155.861M Number of Employees 503 Number of Shareholders 26 Price to Earnings Ratio ( TTM ) — Price to Revenue Ratio ( TTM ) 22.1988 Price to Book (FY) 11.6201 Price to Sales (FY) 22.7131 Balance Sheet Quick Ratio ( MRQ ) 7.1997 Current Ratio ( MRQ ) 7.2630 Debt to Equity Ratio ( MRQ ) 0.0141 Net Debt ( MRQ ) -642.407M Total Debt ( MRQ ) 8.999M Total Assets ( MRQ ) 747.45M Operating Metrics Return on Assets ( TTM ) -0.3812 Return on Equity ( TTM ) -0.4504 Return on Invested Capital ( TTM ) -0.4450 Revenue per Employee ( TTM ) 674107.3559 Price History Average Volume (10 day) 1.571M 1-Year Beta 0.7491 52 Week High 58.7200 52 Week Low 21.5600 Dividends Dividends Paid (FY) 0 Dividends Yield (FY) 0 Dividends per Share (FY) 0 Margins Net Margin ( TTM ) -0.6499 Gross Margin ( TTM ) 0.9621 Operating Margin ( TTM ) -0.6784 Pretax Margin ( TTM ) -0.6485 Income Statement Basic EPS (FY) -1.5982 Basic EPS ( TTM ) -1.5783 EPS Diluted (FY) -1.5982 Net Income (FY) -235.259M EBITDA ( TTM ) -245.781M Gross Profit ( MRQ ) 86.899M Gross Profit (FY) 327.732M Last Year Revenue (FY) 339.076M Total Revenue (FY) 339.076M Free Cash Flow ( TTM ) -135.258M
NASDAQ:ACADLong
by MavRich_Trading
2
ACAD ACADIA PHARMACEUTICALS INC 5X GAINS COMING SOON (HODL)many products releasing soon Sector: Health Technology Industry: Biotechnology Employees: 503 ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA. Valuation Market Capitalization 8.373B Enterprise Value (MRQ) 5.922B Enterprise Value/EBITDA (TTM) — Total Shares Outstanding (MRQ) 155.861M Number of Employees 503 Number of Shareholders 26 Price to Earnings Ratio (TTM) — Price to Revenue Ratio (TTM) 22.1988 Price to Book (FY) 11.6201 Price to Sales (FY) 22.7131 Balance Sheet Quick Ratio (MRQ) 7.1997 Current Ratio (MRQ) 7.2630 Debt to Equity Ratio (MRQ) 0.0141 Net Debt (MRQ) -642.407M Total Debt (MRQ) 8.999M Total Assets (MRQ) 747.45M Operating Metrics Return on Assets (TTM) -0.3812 Return on Equity (TTM) -0.4504 Return on Invested Capital (TTM) -0.4450 Revenue per Employee (TTM) 674107.3559 Price History Average Volume (10 day) 1.571M 1-Year Beta 0.7491 52 Week High 58.7200 52 Week Low 21.5600 Dividends Dividends Paid (FY) 0 Dividends Yield (FY) 0 Dividends per Share (FY) 0 Margins Net Margin (TTM) -0.6499 Gross Margin (TTM) 0.9621 Operating Margin (TTM) -0.6784 Pretax Margin (TTM) -0.6485 Income Statement Basic EPS (FY) -1.5982 Basic EPS (TTM) -1.5783 EPS Diluted (FY) -1.5982 Net Income (FY) -235.259M EBITDA (TTM) -245.781M Gross Profit (MRQ) 86.899M Gross Profit (FY) 327.732M Last Year Revenue (FY) 339.076M Total Revenue (FY) 339.076M Free Cash Flow (TTM) -135.258M
NASDAQ:ACADLong
by MavRich_Trading
ACAD- Long Term Buy This post will be focused on Acadia Pharmaceuticals, a company focused on treatment for Parkinson’s disease psychosis. ACAD Just recently touched what has been its level of support since end of April. From there ACAD jumped roughly 7% in what seems to be a strong uptrend even after a missing their quarterly earnings target. ACAD has touched resistance roughly 7 times in the past month and a half. As long as nothing dramatic occurs to Acadia Pharmaceuticals, there is a good possibility of ACAD will continue towards resistance. This would be a roughly 12% gain. Locating support and resistance lines may be one of the best techniques to use when analyzing a stock. It can often be a good indicator of where breakthroughs may occur as well as whether to long or short. Please let me know if you have any feedback or if there is anything I missed out. I appreciate the feedback.
NASDAQ:ACADLong
by AHiray